Denali Therapeutics Inc (NASDAQ: DNLI) kicked off on Monday, down -3.12% from the previous trading day, before settling in for the closing price of $21.45. Over the past 52 weeks, DNLI has traded in a range of $14.56-$33.33.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 264.19% over the past five years. While this was happening, its average annual earnings per share was recorded -164.91%. With a float of $124.63 million, this company’s outstanding shares have now reached $143.84 million.
Let’s look at the performance matrix of the company that is accounted for 445 employees. In terms of profitability, gross margin is 102.06%, operating margin of 165.42%, and the pretax margin is 140.13%.
Denali Therapeutics Inc (DNLI) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Denali Therapeutics Inc is 13.40%, while institutional ownership is 88.48%. The most recent insider transaction that took place on Nov 11 ’24, was worth 1,932,665. In this transaction Director of this company sold 59,441 shares at a rate of $32.51, taking the stock ownership to the 9,220 shares. Before that another transaction happened on Nov 07 ’24, when Company’s COFO and Secretary sold 15,558 for $29.91, making the entire transaction worth $465,286. This insider now owns 178,066 shares in total.
Denali Therapeutics Inc (DNLI) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -164.91% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Take a look at Denali Therapeutics Inc’s (DNLI) current performance indicators. Last quarter, stock had a quick ratio of 9.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.76, a number that is poised to hit -0.84 in the next quarter and is forecasted to reach -2.94 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Denali Therapeutics Inc (NASDAQ: DNLI) saw its 5-day average volume 1.64 million, a positive change from its year-to-date volume of 1.06 million. As of the previous 9 days, the stock’s Stochastic %D was 11.59%. Additionally, its Average True Range was 1.17.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 7.65%, which indicates a significant increase from 4.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 47.22% in the past 14 days, which was lower than the 53.63% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $25.74, while its 200-day Moving Average is $23.09. Nevertheless, the first resistance level for the watch stands at $21.31 in the near term. At $21.84, the stock is likely to face the second major resistance level. The third major resistance level sits at $22.24. If the price goes on to break the first support level at $20.38, it is likely to go to the next support level at $19.97. The third support level lies at $19.44 if the price breaches the second support level.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
The company with the Market Capitalisation of 2.99 billion has total of 143,922K Shares Outstanding. Its annual sales at the moment are 330,530 K in contrast with the sum of -145,220 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -107,190 K.
